Molecular marker of miR-10386 for identifying skeletal muscle exosome and verification method

Through transcriptome sequencing and cytology verification of miR-10386, the problem of skeletal muscle exosome identification was solved. It was found that it was specifically highly expressed in skeletal muscle exosomes and promoted myoblast proliferation and differentiation, achieving bone Effective identification of myosomes.

CN118910285APending Publication Date: 2024-11-08SOUTHWEST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411310499.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art lacks effective molecular methods for identifying skeletal muscle exosomes, resulting in the inability to accurately identify exosomes of specific tissue types.

Method used

MiR-10386 was used as a molecular marker for identifying skeletal muscle exosomes, and it was verified through transcriptome sequencing and cytologic functional studies to specifically express high expression in skeletal muscle exosomes, and promoted myoblast proliferation and differentiation.

Benefits of technology

miR-10386 is specifically highly expressed in skeletal muscle exosomes, which significantly promotes myoblast proliferation and differentiation, providing a reliable method for identifying skeletal muscle exosomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910285A_ABST
    Figure CN118910285A_ABST
Patent Text Reader

Abstract

The invention discloses miR-10386 as a molecular marker for identifying skeletal muscle exosomes and a verification method of the molecular marker, and belongs to the technical field of molecular biological markers. The application of the miR-10386 as the molecular marker for identifying the skeletal muscle exosome comprises the following step of sequentially verifying that the miR-10386 can be specifically and highly expressed in the skeletal muscle exosome, can promote myoblast proliferation and can promote myoblast differentiation. The research finds that the miR-10386 is specifically and highly expressed in skeletal muscle exosomes, but is extremely low in expression quantity and even not expressed in skeletal muscle tissues. According to cytology function research tests, the miR-10386 can promote myoblast proliferation and differentiation and regulate and control the development process of skeletal muscle, so that the miR-10386 can be used as a molecular marker for identifying skeletal muscle exosomes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of molecular biological markers, and specifically relates to miR-10386 as a molecular marker for identifying skeletal muscle exosomes and a verification method thereof. Background Art

[0002] Skeletal muscle is the main muscle tissue of animals, and its production is subject to complex and strict regulation. In addition to myogenic regulatory factors and myogenic enhancer factors, other genes and small RNAs (such as microRNA) can also participate in the skeletal muscle development process as regulatory molecules.

[0003] MicroRNA (miRNA) is a type of non-coding single-stranded RNA molecule with a length of about 22 nucleotides encoded by endogenous genes, which participates in the post-transcriptional regulation of gene expression in animals and plants. A large number of studies have shown that miRNA regulates the development of skeletal muscle, mainly in the biological processes such as the activation and proliferation, differentiation, and formation of muscle satellite cells. The proliferation and differentiation of myoblasts are important stages in the process of muscle development, and miRNAs play an important role in this stage. MiRNAs in skeletal muscle and other tissues have important regulatory functions. In recent years, studies have gradually found that exosomes, as an important intercellular communication medium, also contain abundant miRNAs. Therefore, the study of the related functions of skeletal muscle exosomes and the miRNAs encapsulated therein has gradually become a hot topic and focus, but there is currently no molecular method for the identification of skeletal muscle exosomes. In the past, skeletal muscle-specific miRNAs, such as miR-1, miR-133, and miR-206, were usually selected to quantitatively determine the tissue type of skeletal muscle tissue by real-time fluorescence q-PCR and identify skeletal muscle tissue. However, the identification of exosomes can only be based on exosome surface protein markers using flow cytometry and protein immunoblotting (Western Blot, WB) and other techniques, which makes it impossible to identify exosomes from specific tissue types. Summary of the invention

[0004] In view of this, the object of the present invention is to provide miR-10386 as a molecular marker for identifying skeletal muscle exosomes and a verification method thereof.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] The invention provides the use of miR-10386 as a molecular marker for identifying skeletal muscle exosomes.

[0007] Furthermore, the following steps are included to sequentially verify that miR-10386 can be specifically and highly expressed in skeletal muscle exosomes, can promote myoblast proliferation, and can promote myoblast differentiation.

[0008] Furthermore, miR-10386 was specifically and highly expressed in skeletal muscle exosomes through transcriptome sequencing.

[0009] Furthermore, the transcriptome sequencing step includes: isolating exosomes and total RNA from skeletal muscle tissues from different sources, extracting total RNA from skeletal muscle exosomes using TRIzol LS, extracting total RNA from skeletal muscle using TRIzol, performing single-end sequencing (36 bp) using Illumina HiSeq 2500, and comparing and analyzing the sequencing results.

[0010] Furthermore, the implementation process of promoting myoblast proliferation is as follows: myoblasts are cultured in DMEM medium containing 10% fetal bovine serum; in the cell proliferation experiment, RibobioFECT TM The cells were transfected with CP reagent and the cell proliferation was evaluated; after transfection, myoblasts were exposed to 10 μM EdU, followed by incubation, EdU staining, and image analysis after microscopy.

[0011] Furthermore, the implementation process of promoting myoblast differentiation is as follows: when the cells reach 80% confluence, the differentiation is induced by replacing the culture medium with 2% horse serum; 6 hours after transfection of miR-10386 mimics, inhibitors and their corresponding negative controls, the culture medium is replaced with differentiation medium and transfected once, and the cells are collected after standing for a preset time; the differentiation of myoblasts is determined by immunofluorescence staining to detect skeletal muscle fast fiber myosin heavy chain and slow fiber myosin heavy chain, and the protein expression level is determined by the number of fluorescence values.

[0012] The beneficial effects of the present invention are:

[0013] The present invention found that miR-10386 is specifically highly expressed in skeletal muscle exosomes, but is expressed at a very low level or even not expressed in skeletal muscle tissue. According to cytological functional research experiments, miR-10386 can promote myoblast proliferation and differentiation and regulate the development process of skeletal muscle. Therefore, miR-10386 can be used as a molecular marker to identify skeletal muscle exosomes.

[0014] Other advantages, objectives and features of the present invention will be described in the following description and will be apparent to those skilled in the art to some extent, or those skilled in the art may be taught from the practice of the present invention. The objectives and other advantages of the present invention may be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to make the purpose, technical solution and beneficial effects of the invention clearer, the present invention provides the following drawings for illustration:

[0016] Figure 1 This is a diagram showing the overall expression of miR-10386 in skeletal muscle and its exosomes;

[0017] Figure 2 This is a diagram showing the expression of miR-10386 in skeletal muscle and its exosome samples of the present invention;

[0018] Figure 3 This is the expression difference fold diagram of miR-10386 in skeletal muscle and its exosomes of the present invention;

[0019] Figure 4 This is a graph showing changes in the expression of miR-10386 during myoblast proliferation at 12, 24, 36, and 48 hours;

[0020] Figure 5 This is a transfection efficiency detection diagram of miR-10386 of the present invention;

[0021] Figure 6 This is the CCK8 detection diagram of miR-10386 in the present invention at 12, 24, 36, and 48 hours of myoblast proliferation;

[0022] Figure 7 This is the EdU detection diagram of miR-10386 of the present invention at 12, 24, 36, and 48 hours of C2C12 proliferation;

[0023] Figure 8 This is the EdU quantification diagram of the present invention;

[0024] Fig. 9 This is a graph showing changes in the expression of miR-10386 in myoblast differentiation on days 0, 2, and 4;

[0025] Fig.10 This is a graph for detecting the differentiation transfection efficiency of miR-10386 of the present invention;

[0026] Fig.11 This is a graph showing the expression of differentiation marker genes after myoblasts differentiated for four days;

[0027] Fig.12 This is a detection diagram of the expression of fast and slow muscle marker genes after four days of myoblast differentiation of the present invention;

[0028] Fig.13 This is the immunofluorescence image of MyHCIIa in myoblasts differentiated for four days of the present invention;

[0029] Fig.14 This is the immunofluorescence quantification diagram of MyHCIIa of the present invention;

[0030] Fig.15This is the MyHCIIx immunofluorescence image of the myoblasts differentiated for four days of the present invention;

[0031] Fig.16 This is a diagram of the immunofluorescence quantification of MyHCIIx of the present invention. DETAILED DESCRIPTION

[0032] The corresponding noun expressions of the present invention are:

[0033] The longissimus dorsi muscle is HC-L; the psoas major muscle is HC-P; the exosomes of the longissimus dorsi muscle are HC-L-exo; and the exosomes of the psoas major muscle are HC-P-exo.

[0034] In the present invention, the longissimus dorsi and the psoas major belong to two skeletal muscles in different locations and with different metabolic types. The purpose of doing two tissues is to prove the consistency of our results on different skeletal muscle tissues.

[0035] Expression: RNA transcription expression of genes in tissues or cells;

[0036] Overexpression: refers to a higher expression level of miR-10386.

[0037] Example 1

[0038] S1. Transcriptome sequencing revealed that miR-10386 is specifically highly expressed in skeletal muscle exosomes:

[0039] Exosomes and total RNA were isolated from skeletal muscle tissues from different sources. The steps for skeletal muscle exosome isolation were as follows: first, the muscle tissue without fascia and fat was minced and homogenized with a tissue homogenizer, and the homogenized tissue was dissolved and separated with PBS; second, the solution was filtered through gauze, centrifuged at 2000g for 30 minutes to remove tissue and cell debris, and then centrifuged at 12000g for 45 minutes to remove any remaining cell debris; third, the supernatant was filtered through a 0.2μm filter membrane to remove any remaining cell debris or impurities; the mixture was then centrifuged at 16000g for 2 hours; fourth, the precipitate was dissolved in PBS, centrifuged at 12000g for 1 hour, and then re-dissolved in PBS; fifth, the exosome separation and purification kit of Guangzhou Ribo Biotechnology Co., Ltd. (Ribobio, Guangzhou, China) was used, including exosome identification, RNA extraction and subsequent in vitro cell experiments to ensure purification.

[0040] Total RNA isolation: First, total RNA was extracted from skeletal muscle exosomes (SKM-Exos) using TRIzol LS (Thermo Fisher Scientific), and RNA was extracted from skeletal muscle using TRIzol (Takara Biotech, Wuhan); second, the extracted RNA was sent to Novo Biotech Co., Ltd. (Tianjin, China) for miRNA transcriptome sequencing; third, the amount and purity of total RNA were evaluated using Agilent Bioanalyzer 2100 and RNA 6000 Nano LabChip Kit, with a RIN value of more than 7.0; fourth, according to the requirements of Illumina TruSeq Small RNA Sample Prep Kits (Illumina), about 1 μg of total RNA was used to prepare small RNA libraries, and single-end sequencing (36 bp) was performed using Illumina HiSeq 2500, and the sequencing results were compared and analyzed; fifth, after quality control of the original sequencing data, the length distribution statistics of clean reads were performed, and small RNA annotation, known miRNA annotation, new miRNA prediction (with reference genome), miRNA differential gene analysis, etc., identify miRNA expression, and screen candidate functional miRNAs.

[0041] S2. Analysis revealed that skeletal muscle exosome miR-10386 can promote myoblast proliferation:

[0042] First, C2C12 myoblasts (Wuhan Purcell Biotechnology Co., Ltd., Wuhan, China) were cultured in DMEM medium containing 10% fetal bovine serum (Gibco) and maintained at 37°C and 5% CO Second, miR-10386 mimics, inhibitors, and their corresponding negative controls (NCs) were provided by Guangzhou Ribo Biotechnology Co., Ltd. (RiboBio); in the cell proliferation experiment, RibobioFECT TM CP reagent for transfection, third, cell proliferation was assessed by CellCounting Kit 8, and fourth, for Edu analysis, C2C12 cells were exposed to 10 μ m Edu 24 h after transfection, followed by an additional 14 h incubation for EdU staining, and images were acquired using an Olympus IX53 microscope, and image analysis was performed using ImageJ software.

[0043] S3. Analysis revealed that skeletal muscle exosome miR-10386 can promote myoblast differentiation:

[0044] First, when the cells reached 80% confluency, they were induced to differentiate by replacing the culture medium with differentiation medium (DM) containing 2% horse serum (Gibco, Carlsbad, CA); second, 6 h after transfection with miR-10386 mimics, inhibitors, and their corresponding negative controls (NC), the culture medium was replaced with differentiation medium (DM), and transfection was performed every 48 h thereafter. (In the cell differentiation experiment, the Thermo Fisher Scientific 2000 reagent for transfection), and the cells were collected on the 6th day; third, the differentiation of C2C12 myoblasts was determined by immunofluorescence staining to detect skeletal muscle fast fiber myosin heavy chain (MyHCIIx) and slow fiber myosin heavy chain (MyHCIIa); fourth, ImageJ software was used to analyze the number of fluorescence values ​​to determine the expression level of the protein.

[0045] in conclusion:

[0046] In step S1 of the present invention, miRNA sequencing is performed on HC-L and HC-P in pig skeletal muscle, and exosomes HC-L-exo and HC-P-exo derived therefrom, and the miRNA sequence is obtained from Figure 1 It was found that miR-10386 was expressed at very low levels in skeletal muscle tissue and was specifically highly expressed in skeletal muscle exosomes; Figure 2 The expression of miR-10386 in different samples was found to be several times higher in skeletal muscle exosomes than in skeletal muscle tissue, and the expression was consistent in the longissimus dorsi and psoas major muscles. Figure 3 It was found that the expression level in HC-L-exo was nearly 6 times higher than that in HC-L, and the expression level in HC-P-exo was more than 9 times higher than that in HC-P. Therefore, miR-10386 may be an important exosomal miRNA regulating skeletal muscle development.

[0047] In step S2 of the present invention, by analyzing the expression changes of miR-10386 during the proliferation of C2C12 cells, Figure 4 It was found that during the proliferation of C2C12 cells, the expression of miR-10386 showed an upward trend, and at 24h and 36h, the expression level increased significantly (P<0.01). Therefore, the present invention overexpressed miR-10386 by synthesizing mimics to study its effect on myoblast proliferation. miR-10386 mimics and negative control (NC) were transfected into C2C12 cells, respectively. Figure 5 The results showed that the expression level of miR-10386 was significantly increased after transfection (P<0.001), meeting the requirements of subsequent experiments. Figure 6The CCK-8 results showed that compared with the control group, the absorbance of C2C12 cells overexpressing miR-4331-3p at 450nm increased significantly at 0h-12h and 12-24h (P<0.05), and the difference in absorbance between the cells and the control group at 36h was extremely significant (P<0.001). Figure 7 , 8 Further EdU analysis revealed that the number of newborn cells increased significantly after overexpression of miR-1038p, indicating that miR-10386 significantly promoted the proliferation of myoblasts.

[0048] In step S3 of the present invention, Fig. 9 The results showed that the expression of miR-10386 increased significantly during the cell differentiation stage (P<0.05). Subsequently, miR-10386 mimics was transfected into differentiated C2C12 cells to overexpress them, in order to explore the regulatory role of miR-4331-3p in the terminal differentiation of myoblasts. Fig.10 The results showed that after transfection with mimics, the expression level of miR-10386 in C2C12 cells was significantly increased (P<0.001), meeting the requirements of subsequent experiments. Fig.11 It can be seen that q-PCR analysis of the three myogenic differentiation factors MYOD, MYOG and MYHC showed that the overexpression of miR-10386 significantly promoted the expression of these myogenic differentiation marker genes (P<0.01). Fig.12 The results showed that further q-PCR analysis of myofiber subtype myosin heavy chain genes revealed that overexpression of miR-10386 significantly promoted the expression of MyHCⅠ, MyHCⅡa, MyHCⅡb, and MyHCⅡx; Figure 13-16 Further immunofluorescence analysis revealed that overexpression of miR-4331-3p significantly increased the number of fast muscle (MyHCⅡx) and slow muscle fibers (MyHCⅡa). The above indicates that overexpression of miR-10386 promotes the differentiation of myoblasts and fast and slow machines.

[0049] The analysis of the present invention shows that miR-10386 is not only specifically and highly expressed in skeletal muscle exosomes, but also participates in the process of skeletal muscle development, which functionally confirms that it can be used as a candidate molecular marker for identifying skeletal muscle exosomes.

[0050] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. Use of miR-10386 as a molecular marker for identifying skeletal muscle exosomes.

2. The method for validating miR-10386 as a molecular marker for identifying skeletal muscle exosomes according to claim 1, Features: The method includes the following steps, which sequentially verify that miR-10386 can be specifically and highly expressed in skeletal muscle exosomes, can promote myoblast proliferation, and can promote myoblast differentiation.

3. The method for validating miR-10386 as a molecular marker for identifying skeletal muscle exosomes according to claim 2, Features: miR-10386 was specifically and highly expressed in skeletal muscle exosomes through transcriptome sequencing.

4. The method for validating miR-10386 as a molecular marker for identifying skeletal muscle exosomes according to claim 3, Features: The steps of transcriptome sequencing include: isolating exosomes and total RNA from skeletal muscle tissues from different sources, extracting total RNA from skeletal muscle exosomes using TRIzol LS, extracting total RNA from skeletal muscle using TRIzol, performing single-end sequencing (36 bp) using Illumina HiSeq 2500, and comparing and analyzing the sequencing results.

5. The method for validating miR-10386 as a molecular marker for identifying skeletal muscle exosomes according to claim 2, Features: The implementation process of promoting myoblast proliferation is as follows: myoblasts were cultured in DMEM medium containing 10% fetal bovine serum; in the cell proliferation experiment, RibobioFECT TM The cells were transfected with CP reagent and the cell proliferation was evaluated; after transfection, myoblasts were exposed to 10 μM EdU, followed by incubation, EdU staining, and image analysis after microscopy.

6. The method for validating miR-10386 as a molecular marker for identifying skeletal muscle exosomes according to claim 2, Features: The implementation process of promoting myoblast differentiation is as follows: when the cells reach 80% confluence, the differentiation is induced by replacing the culture medium with 2% horse serum; 6 hours after transfection of miR-10386 mimics, inhibitors and their corresponding negative controls, the culture medium is replaced with differentiation medium and transfected once, and the cells are collected after standing for a preset time; the differentiation of myoblasts is determined by immunofluorescence staining to detect skeletal muscle fast fiber myosin heavy chain and slow fiber myosin heavy chain, and the protein expression level is determined by the number of fluorescence values.